Article Correctness Is Author's Responsibility: PACIFIC survival rates explained: Lung cancer spread reduced, new distant growth most often in the brain

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The update, which provides greater insight into the landmark study that changed the standard of care for patients with stage 3 unresectable non-small-cell lung cancer (NSCLC), were presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO).